Announcements

Horizon Scanning in Onkology - Reports

We are pleased to introduce two new HSO reports.

DSD HSO No. 39
Pomalidomide (Pomalyst®) for the ? 3rd-line therapy of patients with relapsed and refractory multiple myeloma

DSD HSO No. 40
Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC)

More...

Horizon Scanning in Onkology - Reports

We are pleased to introduce our new HSO report.

DSD HSO No. 38
Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer

More...

Cervical cancer screening: p16/KI-67 Dual Stain test (CINtec® PLUS) in the triage of equivocal results or mild to moderate dysplasia in pap cytology

Each year around 30 000 women in Austria receive a PAPIII or PAPIIID cytology result during routine cervical cancer screening. Roughly equivalent to ASC-US or LSIL cytology, the risk of progression to cancer for these patients is unclear and requires further diagnostic investigation: for many of the women the ensuing procedures and potential adverse effects turn out to be unnecessary. The p16/Ki-67 Dual Stain test (CINtec® PLUS) claims to improve the triage of these women. In a systematic review though we could not identify sufficient evidence to support the utility of the p16/Ki-67 Dual Stain test in the triage of equivocal or mild to moderate dysplasia results in Austria.

Publication: LBI-HTA Project report No. 72: https://eprints.aihta.at/1009/

Contact: Agnes Kisser

More...